Adocia re-acquires exclusive rights to insulin analog from US drug major

French biotech firm Adocia (Euronext Paris: ADOC) has agreed with US pharma major Eli Lilly (NYSE: LLY) not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone technology for the formulation of fast acting insulin analog formulated with the BioChaperone technology. Consequently, the two companies have terminated the collaboration.

“We intend to pursue more actively this project by ourselves as the phase I clinical trial met the predefined clinical endpoints, hence confirming the great potential of our BioChaperone technology,” said Gerard Soula, president and chief executive of Adocia.

“Our plan is to test a BioChaperone insulin analog formulation on type 1 diabetic patients. For this, we intend to conduct a clinical trial, before year end in Germany, on one or more formulations of insulin analog. This trial will be carried out in parallel to the one already scheduled with HinsBet, our formulation of human insulin” said Olivier Soula, deputy general manager and director R&D, Adocia.